There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oncternal Therapeutics (ONCT – Research Report) and Cutera (CUTR – Research Report) with bullish sentiments. Oncternal Therapeutics (ONCT) Maxim Group analyst Jason McCarthy maintained a Buy rating on Oncternal Therapeutics yesterday and set a price target of $3.50. The company's shares closed last Friday at $0.90, close to its 52-week low of $0.69. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-oncternal-therapeutics-onct-and-cutera-cutr?utm_source=advfn.com&utm_medium=referral
Oncternal Therapeutics (NASDAQ:ONCT)
Gráfico Histórico do Ativo
De Jan 2023 até Fev 2023 Click aqui para mais gráficos Oncternal Therapeutics.
Oncternal Therapeutics (NASDAQ:ONCT)
Gráfico Histórico do Ativo
De Fev 2022 até Fev 2023 Click aqui para mais gráficos Oncternal Therapeutics.